This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales
by Zacks Equity Research
Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.
UTMDNegative Net Change
earnings medical
UnitedHealth (UNH) Q2 Success: A Turnaround Worth Investing in?
by Kaibalya Pravo Dey
UnitedHealth (UNH) is navigating its challenges effectively, maintaining a positive outlook for the future while demonstrating a strong commitment to its clients and shareholders.
UNHPositive Net Change MOHPositive Net Change ELVPositive Net Change
earnings-outlook hmo medical
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales, along with strength in all the product lines.
ABTNegative Net Change BSXPositive Net Change DGXPositive Net Change ITGRPositive Net Change
earnings medical medical-devices
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
BSXPositive Net Change ISRGPositive Net Change GMEDPositive Net Change HQYPositive Net Change
medical medical-devices
Centene (CNC) Q2 Earnings Miss on Declining Medicaid Membership
by Zacks Equity Research
Centene's (CNC) second-quarter earnings suffer from rising operating expenses and a decline in Medicaid membership levels. Improved Marketplace membership growth partially offset the negatives.
UNHPositive Net Change HCAPositive Net Change CNCPositive Net Change ELVPositive Net Change
earnings medical
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect strong performance in the Diagnostics segment.
MCKPositive Net Change AXGNNegative Net Change NARINegative Net Change RVTYPositive Net Change
medical medical-devices
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
by Zacks Equity Research
Avanos' (AVNS) strong product line and focus on R&D raise optimism about the stock.
BSXPositive Net Change UHSPositive Net Change HOLXPositive Net Change AVNSPositive Net Change
medical medical-devices
DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth. Shares fall.
DGXPositive Net Change UHSPositive Net Change DXCMNegative Net Change ABMPositive Net Change
medical medical-devices
Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions
by Zacks Equity Research
Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.
DGXPositive Net Change UHSPositive Net Change HOLXPositive Net Change HAEPositive Net Change
medical medical-devices
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.
BMYPositive Net Change PFEPositive Net Change CORTPositive Net Change TRDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
by Urmimala Biswas
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ICLR, OGN and DOCS are set to gain the most. Healthcare staffing shortages are leading to an increase in labor wages.
ICLRPositive Net Change OGNPositive Net Change DOCSPositive Net Change
hospitals medical
Zacks Industry Outlook Highlights UnitedHealth, The Cigna and Centene
by Zacks Equity Research
UnitedHealth, The Cigna and Centene are part of the Zacks Industry Outlook article.
UNHPositive Net Change CIPositive Net Change CNCPositive Net Change
medical
Implied Volatility Surging for United Therapeutics (UTHR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to United Therapeutics (UTHR) stock based on the movements in the options market lately.
UTHRPositive Net Change
medical medical-devices
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.
ABTNegative Net Change ISRGPositive Net Change HAEPositive Net Change ICLRPositive Net Change
earnings medical
Should You Invest in Novo Nordisk (NVO) Ahead of Q2 Earnings?
by Ahan Chakraborty
Novo Nordisk's (NVO) second-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pe-ratio pharmaceuticals
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
GSKPositive Net Change PFEPositive Net Change MRKNegative Net Change MRNAPositive Net Change
biotechs earnings-preview medical messenger-rna pharmaceuticals vaccines
Amedisys (AMED) Q2 Earnings Top Estimates, Gross Margin Down
by Zacks Equity Research
Amedisys (AMED) delivers year-over-year growth in all three of its segmental revenues in the second quarter of 2024.
ABTNegative Net Change AMEDPositive Net Change DGXPositive Net Change ISRGPositive Net Change
earnings medical medical-devices
Lower Volume Likely to Hurt GE HealthCare's (GEHC) Q2 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) second-quarter results are likely to witness declining segmental revenues in imaging, ultrasound and patient care. The bottom-line results may reflect better pricing.
MCKPositive Net Change AXGNNegative Net Change NARINegative Net Change GEHCPositive Net Change
medical medical-devices
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
by Zacks Equity Research
Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.
DGXPositive Net Change UHSPositive Net Change HAEPositive Net Change TRUMYPositive Net Change
medical medical-devices
Alphatec's (ATEC) New EOS Insight System to Boost Spine Care
by Zacks Equity Research
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
BSXPositive Net Change UHSPositive Net Change HOLXPositive Net Change ATECPositive Net Change
medical medical-devices
Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
ECLPositive Net Change MCKPositive Net Change AXGNNegative Net Change NARINegative Net Change
medical medical-devices
Universal Health (UHS) Q2 Earnings Beat on Acute Care Strength
by Zacks Equity Research
Universal Health's (UHS) second-quarter results benefit from the rising number of patients in the Acute Care Unit. Declining admissions in the Behavioral Health segment partially offset the positives.
UNHPositive Net Change UHSPositive Net Change HCAPositive Net Change ELVPositive Net Change
earnings medical
Viking (VKTX) Q2 Earnings Beat, Stock Up on Pipeline Updates
by Zacks Equity Research
Viking (VKTX) gains 24% on better-than-expected second-quarter 2024 results, along with encouraging updates regarding its pipeline development plans.
ANIPPositive Net Change VKTXPositive Net Change RAPTPositive Net Change ANVSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zacks Initiates Coverage of Vaso With Neutral Recommendation
by Debanjana Dey
Discover why Zacks rates Vaso as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore VASO's strategic market presence and financial health amid market challenges.
VASOPositive Net Change
medical medical-devices
Here's How Zimmer Biomet (ZBH) is Poised Ahead of Q2 Earnings
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed procedure volume recovery banking on strategic product launches in the second quarter.
QGENPositive Net Change ZBHPositive Net Change PENNegative Net Change HIMSNegative Net Change
earnings medical